Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
7.50    -0.40 (-5.06%)
Bid:
7.00
Ask:
8.00
Spread: 1.00 (14.286%)
Market Cap: £474.94m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Allergy Thera. News

Allergy Therapeutics screens first patients in grass pollen study
26 Oct 2020

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study '...

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost
23 Sep 2020

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform
4 Sep 2020

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax
3 Sep 2020

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications be...

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall
15 Jul 2020

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Allergy Therapeutics revenues grow despite Covid-19 disruption
15 Jul 2020

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from ...

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial
9 Jul 2020

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Allergy Therapeutics pleased with invalidation of B301 trial data
9 Jul 2020

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Pau...